Table 2. Clinical and molecular pathological features of primary GBM samples in association with MMP9 expression.
| Total (n = 78) | Low(n = 39) | High(n = 39) | p value |
|---|---|---|---|
| Gender | |||
| Male | 22 | 24 | 0.818 |
| Female | 17 | 15 | |
| Age at diagnosis | |||
| ≤45 | 23 | 9 | 0.002 |
| >45 | 16 | 30 | |
| Preoperative KPS score | |||
| ≥80 | 24 | 19 | 0.362 |
| <80 | 15 | 20 | |
| MGMT | |||
| Methylated | 20 | 9 | 0.017 |
| Unmethylated | 18 | 29 | |
| NA | 1 | 1 | |
| IDH1 | |||
| Mutation | 11 | 0 | <0.001 |
| Wild type | 28 | 39 | |
| TMZ chemotherapy | |||
| Yes | 28 | 22 | 0.157 |
| No | 11 | 17 | |
| Extent of resection | |||
| Total | 15 | 12 | 0.634 |
| Subtotal | 24 | 27 |
Abbreviations: IDH1, isocitrate dehydrogenase 1; KPS, Karnofsky performance scale; MGMT, O6-methylguanine-DNA methyltransferase; TMZ, temozolomide. NA, not available. P values were determined using a 2-sided chi-square test of variance.